Literature DB >> 9090576

Mirtazapine: clinical advantages in the treatment of depression.

G D Burrows1, C M Kremer.   

Abstract

Mirtazapine is a noradrenergic and specific serotonergic antidepressant, characterized by a unique pharmacologic profile, favorable pharmacokinetics, and proven efficacy and safety. Mirtazapine has demonstrated clinical efficacy in the treatment of moderately and severely depressed patients. In addition, mirtazapine was found to be equally effective as clomipramine in the treatment of severely depressed, hospitalized patients. The overall improvement with mirtazapine is seen after 1 week of treatment and is sustained throughout the treatment period. It is paralleled by an improvement in depressed mood, the core symptom of depressive illness. Because of its unique pharmacologic profile, mirtazapine is virtually devoid of anticholinergic, adrenolytic, and serotonin-related side effects. The most frequently reported adverse events were transient sedation and weight gain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9090576     DOI: 10.1097/00004714-199704001-00005

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  5 in total

1.  Treatment of depression as part of end-of-life care.

Authors:  Breffni Hannon; Peter Fitzgerald; Marie Murphy
Journal:  BMJ Case Rep       Date:  2008-11-20

Review 2.  A risk-benefit assessment of mirtazapine in the treatment of depression.

Authors:  S Kasper; N Praschak-Rieder; J Tauscher; R Wolf
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

Review 3.  New formulations of existing antidepressants: advantages in the management of depression.

Authors:  Trevor R Norman; James S Olver
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

4.  Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice.

Authors:  Tamara Bittolo; Carlo Antonio Raminelli; Chiara Deiana; Gabriele Baj; Valentina Vaghi; Sara Ferrazzo; Annalisa Bernareggi; Enrico Tongiorgi
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

5.  Protective role of mirtazapine in adult female Mecp2+/- mice and patients with Rett syndrome.

Authors:  Javier Flores Gutiérrez; Claudio De Felice; Giulia Natali; Silvia Leoncini; Cinzia Signorini; Joussef Hayek; Enrico Tongiorgi
Journal:  J Neurodev Disord       Date:  2020-09-28       Impact factor: 4.025

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.